

g aggaggct**Ag** cgggaaagtg gtgcaggata taatgccgtg cctgcatttc
gtgaaggggg aggagaagga gccgtcgaag gag**AgcAgc** gcggcacgaa gaagctgagc
gaggagggtga agacgacgga gcagaagagg gaggcctgca agtgcatagt gcgcgccacg
aagggcatct ccggtatcaa aaatgaactt gtcgccgagg tccccaagaa gtgcgatatt
aagaccactc tcccgcccat caccgccgac ttcgactgct ccaagatcca aagtactatt
ttcagagggtt actat

GGATTC

caag aaacc**Agc**gg gactatggtg agagcgctga tgccgtgcct gccgttcgtg
caggggaaag agaaagagcc gtcaaagggg **AgcAgc**cagcg gcgcaaaaag attggacggg
gagacgaaga cggggccgca gaggggtgcac gcttgtgagt gcatccagac cgccatgaag
acttattccg acatcgacgg gaaactcgtc agcgagggtcc ccaagcactg cggcatcggt
gacagcaagc tcccgcccat tgacgtcaac atggactgca agacagttgg agtggttcct
cggcaacccc aacttccagt ctctctccgt catgggtccc tcacggggcc aagtgatccc
gcccacaaag cacggttgga gagaccccag attagagttc cgccccccgc accggaaaaa
gcc TAA

Fig. 1

2/9

1 50
EEASGKVVQD IMPCLH FVKG EEKEPSKESS SGTKKLSEEV KTTEQKREAC

51 100
KCIVRATKGI SGIKNELVAE VPKKCDIKTT LPPITADFDC SKIQSTIFRG

101 150
YYGFQETSGT MVRALMPCLP FVQGKEKEPS KGSSSGAKRL DGETKTGPQR

151 200
VHACECIQTA MKTYS DIDGK LVSEVPKHCG IVDSKLPPID VNMDCKTVGV

201 243
VPRQPQLPVS LRHGPVTGPS DPAHKARLER PQIRVPPPAP EKA

Fig.2




FIG. 3





Fig 4

Binding inhibition
ELISA


| | Dimer W.T | PjEDcys |
|-----------|-----------|---------|
| Patient 1 | 68% | 7% |
| Patient 2 | 56% | 3,5% |
| Patient 3 | 62% | 10% |
| Patient 4 | 62% | 8% |
| Patient 5 | 62% | 8% |

Fig. 5


6/9




—◆— rPj1+rPj2 Mix — — PjEDcys



—◆— rPj1+rPj2 Mix — — PjEDcys



—◆— rPj1+rPj2 Mix — — PjEDcys



—◆— rPj1+rPj2 Mix — — PjEDcys

Fig. 6




Fig 7

**% of human IgE
binding inhibition**

| <i>P. judaica</i> extract | ExPj | rParj1 | rParj2 | rParj1 rParj2 |
|------------------------------|------|--------|--------|------------------|
| Patient 1 | 94 | 10 | 80 | 80 |
| Patient 2 | 93 | 53 | 74 | 74 |
| Patient 3 | 90 | 35 | 37 | 80 |
| Patient 4 | 98 | 59 | 85 | 86 |
| Patient 5 | 100 | 57 | 29 | 67 |
| Patient 6 | 91 | 29 | 65 | 69 |
| Patient 7 | 94 | 38 | 58 | 79 |
| Average | 94,3 | 40,1 | 61,1 | 76,5 |

Fig. 8

**% of human IgE
binding inhibition**

| tested Protein | % of inhibition |
|-----------------------|------------------------|
| rParj 1 | 95% |
| PjA | 16% |
| PjB | 85% |
| PjC | 14% |
| PjD | 15% |

Fig. 9